Literature DB >> 25511521

Anterior cingulate dopamine turnover and behavior change in Parkinson's disease.

Catherine L Gallagher1,2,3, Brian Bell4, Matthew Palotti5,4, Jen Oh6, Bradley T Christian7,8, Ozioma Okonkwo6,9, Jitka Sojkova5,4,6, Laura Buyan-Dent4, Robert J Nickles7, Sandra J Harding6,9, Charles K Stone9, Sterling C Johnson5,6,9, James E Holden7.   

Abstract

Subtle cognitive and behavioral changes are common in early Parkinson's disease. The cause of these symptoms is probably multifactorial but may in part be related to extra-striatal dopamine levels. 6-[(18) F]-Fluoro-L-dopa (FDOPA) positron emission tomography has been widely used to quantify dopamine metabolism in the brain; the most frequently measured kinetic parameter is the tissue uptake rate constant, Ki. However, estimates of dopamine turnover, which also account for the small rate of FDOPA loss from areas of specific trapping, may be more sensitive than Ki for early disease-related changes in dopamine biosynthesis. The purpose of the present study was to compare effective distribution volume ratio (eDVR), a metric for dopamine turnover, to cognitive and behavioral measures in Parkinson's patients. We chose to focus the investigation on anterior cingulate cortex, which shows highest FDOPA uptake within frontal regions and has known roles in executive function. Fifteen non-demented early-stage PD patients were pretreated with carbidopa and tolcapone, a central catechol-O-methyl transferase (COMT) inhibitor, and then underwent extended imaging with FDOPA PET. Anterior cingulate eDVR was compared with composite scores for language, memory, and executive function measured by neuropsychological testing, and behavior change measured using two informant-based questionnaires, the Cambridge Behavioral Inventory and the Behavior Rating Inventory of Executive Function-Adult Version. Lower mean eDVR (thus higher dopamine turnover) in anterior cingulate cortex was related to lower (more impaired) behavior scores. We conclude that subtle changes in anterior cingulate dopamine metabolism may contribute to dysexecutive behaviors in Parkinson's disease.

Entities:  

Keywords:  Adult; Aged; Brain mapping; Cerebral cortex/metabolism/radionuclide imaging; Dihydroxyphenylalanine/*analogs & derivatives/drug effects/pharmacokinetics; Dopamine agents/*diagnostic use/pharmacokinetics; Humans; Parkinson disease/*physiopathology/*radionuclide imaging; Positron emission tomography; Research support/U.S. Gov’t/P.H.S.

Mesh:

Substances:

Year:  2015        PMID: 25511521      PMCID: PMC4469641          DOI: 10.1007/s11682-014-9338-4

Source DB:  PubMed          Journal:  Brain Imaging Behav        ISSN: 1931-7557            Impact factor:   3.978


  41 in total

1.  Cortical 6-[18F]fluoro-L-dopa uptake and frontal cognitive functions in early Parkinson's disease.

Authors:  Anna Brück; Sargo Aalto; Elina Nurmi; Jörgen Bergman; Juha O Rinne
Journal:  Neurobiol Aging       Date:  2005-06       Impact factor: 4.673

Review 2.  Nigral and extranigral pathology in Parkinson's disease.

Authors:  H Braak; E Braak; D Yilmazer; C Schultz; R A de Vos; E N Jansen
Journal:  J Neural Transm Suppl       Date:  1995

3.  Graphical analysis of 6-fluoro-L-dopa trapping: effect of inhibition of catechol-O-methyltransferase.

Authors:  J E Holden; D Doudet; C J Endres; G L Chan; K S Morrison; F J Vingerhoets; B J Snow; B D Pate; V Sossi; K R Buckley; T J Ruth
Journal:  J Nucl Med       Date:  1997-10       Impact factor: 10.057

4.  Effects of catechol-O-methyltransferase inhibition on the rates of uptake and reversibility of 6-fluoro-L-Dopa trapping in MPTP-induced parkinsonism in monkeys.

Authors:  D J Doudet; G L Chan; J E Holden; K S Morrison; R J Wyatt; T J Ruth
Journal:  Neuropharmacology       Date:  1997-03       Impact factor: 5.250

5.  Cognitive profile of patients with newly diagnosed Parkinson disease.

Authors:  Dino Muslimovic; Bart Post; Johannes D Speelman; Ben Schmand
Journal:  Neurology       Date:  2005-10-25       Impact factor: 9.910

6.  Midbrain dopamine and prefrontal function in humans: interaction and modulation by COMT genotype.

Authors:  Andreas Meyer-Lindenberg; Philip D Kohn; Bhaskar Kolachana; Shane Kippenhan; Aideen McInerney-Leo; Robert Nussbaum; Daniel R Weinberger; Karen Faith Berman
Journal:  Nat Neurosci       Date:  2005-04-10       Impact factor: 24.884

7.  A program for neuropsychological investigation of deep brain stimulation (PNIDBS) in movement disorder patients: development, feasibility, and preliminary data.

Authors:  C E Morrison; J C Borod; M F Brin; S A Raskin; I M Germano; D J Weisz; C W Olanow
Journal:  Neuropsychiatry Neuropsychol Behav Neurol       Date:  2000-07

8.  FluoroDOPA PET shows the nondopaminergic as well as dopaminergic destinations of levodopa.

Authors:  W D Brown; M D Taylor; A D Roberts; T R Oakes; M J Schueller; J E Holden; L M Malischke; O T DeJesus; R J Nickles
Journal:  Neurology       Date:  1999-10-12       Impact factor: 9.910

9.  Frontal, midbrain and striatal dopaminergic function in early and advanced Parkinson's disease A 3D [(18)F]dopa-PET study.

Authors:  J S Rakshi; T Uema; K Ito; D L Bailey; P K Morrish; J Ashburner; A Dagher; I H Jenkins; K J Friston; D J Brooks
Journal:  Brain       Date:  1999-09       Impact factor: 13.501

10.  6-[18F]Fluoro-L-DOPA PET studies of the turnover of dopamine in MPTP-induced parkinsonism in monkeys.

Authors:  D J Doudet; G L Chan; J E Holden; E G McGeer; T A Aigner; R J Wyatt; T J Ruth
Journal:  Synapse       Date:  1998-07       Impact factor: 2.562

View more
  7 in total

1.  Dopaminergic correlates of metabolic network activity in Parkinson's disease.

Authors:  Florian Holtbernd; Yilong Ma; Shichun Peng; Frank Schwartz; Lars Timmermann; Lutz Kracht; Gereon R Fink; Chris C Tang; David Eidelberg; Carsten Eggers
Journal:  Hum Brain Mapp       Date:  2015-06-03       Impact factor: 5.038

2.  Physiological Whole-Brain Distribution of [18F]FDOPA Uptake Index in Relation to Age and Gender: Results from a Voxel-Based Semi-quantitative Analysis.

Authors:  Sinn-Rithy Toch; Sylvain Poussier; Emilien Micard; Marc Bertaux; Axel Van Der Gucht; Elodie Chevalier; Pierre-Yves Marie; Eric Guedj; Antoine Verger
Journal:  Mol Imaging Biol       Date:  2019-06       Impact factor: 3.488

3.  Thalamocortical dysrhythmia detected by machine learning.

Authors:  Sven Vanneste; Jae-Jin Song; Dirk De Ridder
Journal:  Nat Commun       Date:  2018-03-16       Impact factor: 14.919

4.  Dopamine, time perception, and future time perspective.

Authors:  Jennifer M Mitchell; Dawn Weinstein; Taylor Vega; Andrew S Kayser
Journal:  Psychopharmacology (Berl)       Date:  2018-07-19       Impact factor: 4.530

5.  Synaptic potentiation of anterior cingulate cortex contributes to chronic pain of Parkinson's disease.

Authors:  Zhaoxiang Zhou; Penghai Ye; Xu-Hui Li; Yuxiang Zhang; Muhang Li; Qi-Yu Chen; Jing-Shan Lu; Man Xue; Yanan Li; Weiqi Liu; Lin Lu; Wantong Shi; Ping-Yi Xu; Min Zhuo
Journal:  Mol Brain       Date:  2021-11-06       Impact factor: 4.041

6.  The Intranigral Infusion of Human-Alpha Synuclein Oligomers Induces a Cognitive Impairment in Rats Associated with Changes in Neuronal Firing and Neuroinflammation in the Anterior Cingulate Cortex.

Authors:  Maria Francesca Palmas; Michela Etzi; Augusta Pisanu; Chiara Camoglio; Claudia Sagheddu; Michele Santoni; Maria Francesca Manchinu; Mauro Pala; Giuliana Fusco; Alfonso De Simone; Luca Picci; Giovanna Mulas; Saturnino Spiga; Maria Scherma; Paola Fadda; Marco Pistis; Nicola Simola; Ezio Carboni; Anna R Carta
Journal:  Cells       Date:  2022-08-24       Impact factor: 7.666

7.  Neurophysiological Biomarkers of Parkinson's Disease.

Authors:  Shani Waninger; Chris Berka; Marija Stevanovic Karic; Stephanie Korszen; P David Mozley; Claire Henchcliffe; Yeona Kang; Jacob Hesterman; Tomer Mangoubi; Ajay Verma
Journal:  J Parkinsons Dis       Date:  2020       Impact factor: 5.568

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.